UNICREDIT BANK/CALL/VERTEX PHARMACEUTICALS/400/0.1/18.12.24 | Market Closed - BOERSE MUENCHEN 01:11:25 22/06/2024 am IST | ||
| 8.26 EUR | -1.55% |
|
| Current month | +13.77% | ||
| 1 month | +31.95% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Latest news about VERTEX PHARMACEUTICALS INCORPORATED
More news
| Date | Price | Change |
|---|---|---|
| 21/24/21 | 8.26 | -1.55% |
| 20/24/20 | 8.39 | +3.20% |
| 19/24/19 | 8.13 | -0.61% |
| 18/24/18 | 8.18 | -5.98% |
| 17/24/17 | 8.7 | -6.75% |
Real-time BOERSE MUENCHEN
Last update June 22, 2024 at 01:11 am IST
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | CALL |
| Underlying | VERTEX PHARMACEUTICALS INCORPORATED |
| Issuer | 
UniCredit
|
| WKN | HC49PW |
| ISIN | DE000HC49PW5 |
| Date issued | 20/02/2023 |
| Strike | 400 $ |
| Maturity | 18/12/2024 (180 Days) |
| Parity | 10 : 1 |
| Emission price | 2.55 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 9.59 € |
|---|---|
| Lowest since issue | 2.09 € |
| Spread | 0.04 € |
| Spread % | 0.49% |
Company Profile
Vertex Pharmaceuticals Incorporated specializes in the research, development and marketing of micromolecular drugs primarily for the treatment of cancers, viral, inflammatory and auto-immune diseases.
Net sales are distributed geographically as follows: the United States (61.2%), Europe (31.5%) and other (7.3%).
Sector
-
Ratings for Vertex Pharmaceuticals Incorporated
Trading Rating
Investor Rating
ESG Refinitiv
B+
Consensus: Vertex Pharmaceuticals Incorporated
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
31
Last Close Price
468.7
USD
Average target price
463.4
USD
Spread / Average Target
-1.13%
- Stock Market
- Warrants
- Warrant
